Clinical Trial

Neuromodulation and Cognitive Training for Substance Use Disorders

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
closed to accrual due to change in practice; no longer seeing eligible participants.
Summary
The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve treatment outcomes.
Protocol Amendment History 5 changes
critical Trial terminated 2026-08-11
critical Trial terminated: closed to accrual due to change in practice; no longer seeing eligible participants. 2026-08-11
notable Enrollment reduced: 80 -> 33 participants 2026-08-11
notable Primary completion moved earlier: 2026-09-01 -> 2026-06-20 2026-08-11
minor Completion moved earlier: 2026-09-01 -> 2026-06-20 2026-08-11
Trial Details
NCT Number NCT04426214
Lead Sponsor University of Minnesota
Conditions Stimulant Use, Alcohol Use Disorder
Enrollment 33 participants
Start Date 2021-07-16
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-06-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-10